2021 Insights on Sjogren’s Syndrome (SS) – Opportunity Analysis and Forecasts to 2029

The “Sjogren’s Syndrome (SS) – Opportunity Analysis and Forecasts to 2029” report has been added to ResearchAndMarkets.com’s offering.

Sjogren’s syndrome (SS) is a chronic and systemic autoimmune inflammatory disorder in which an initial immunological attack that primarily targets the lacrimal and salivary glands. Although most characteristically clinical features are ocular and oral dryness due to reduced secretory functions, systemic features including cutaneous, respiratory, renal, hepatic, neurological, and vascular involvement often occur. In addition, there is a higher incidence of lymphoma associated with SS patients.

The SS market is expected to undergo significant change and moderate growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan) covered in this report. In this report, the publisher analyses the current symptomatic SS treatment landscape and provides detailed insights into the market dynamics of this systemic autoimmune disease. This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for SS, and their sales projections within SS over the 2019-2029 forecast period.

The SS market is expected to undergo significant change and growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan) covered in this report. In this report, the publisher analyzes the current SS symptomatic and systemic treatment landscape and provides detailed insights into the market dynamics of this autoimmune disease. This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for SS, and their sales projections within SS over the 2019-2029 forecast period.

With no currently approved systemic treatments, the SS treatment algorithm varies among physicians and institutions, but is largely consists of off-label therapies, immunosuppressants, and corticosteroids. Over the forecast period the publisher expects that treatment options for SS patients will significantly expand as pipeline products are approved and launched for the systemic treatment of SS. The launches of products with demonstrated efficacy will be a major driver of growth over the next 10 years.

Story continues

Companies Mentioned

• Viela Bio

• Gilead

• Galapagos

• Novartis

• Kronos Bio

• BMS

• GSK

• TearSolutions

Key Questions Answered

• How will the symptomatic and systemic SS treatment landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2019-2029?

• What SS treatments are in clinical development?

• How do the clinical and commercial attributes of SS treatment candidates in development compare with one another, and against conventional treatment options?

• What are the remaining unmet needs in SS diagnosis and treatment?

• What drivers and barriers will affect SS sales in the 7MM over the forecast period?

Reasons to Buy

The report will enable you to –

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the global SS treatment market.

• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SS market in the future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:

1. Table of Contents

2 Sjogren’s Syndrome: Executive Summary

2.1 Growth in the Sjogren’s Syndrome Market Is Expected from 2019 to 2029

2.2 R&D Strategies for the Sjogren’s Syndrome Market

2.3 High Level of Unmet Need Persists in the Sjogren’s Syndrome Marketplace

2.4 The Arrival of Novel Biologics Will Transform the Sjogren’s Syndrome Treatment Paradigm

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.1.3 Symptoms

4.1.4 Prognosis

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.5 Epidemiological Forecast for SS (2019-2029)

5.6 Discussion

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Approval of Treatments for Glandular and Extraglandular Manifestations

7.3 Earlier Sjogren’s Syndrome Diagnosis

7.4 Improved Public and Patient Awareness of Sjogren’s Syndrome

7.5 Better Clinical Trial Endpoints

8 R&D Strategies

8.1 Overview

8.1.1 Evaluation of Biologic Therapies Marketed for Other Autoimmune Diseases

8.1.2 Increasing Efficiency of Clinical Trials

8.2 Clinical Trials Design

8.2.1 Endpoint Selection

8.2.2 Inclusion Criteria

8.2.3 Patient Recruitment

9 Pipeline Assessment

9.1 Overview

9.2 Innovative Early-Stage Approaches

9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/mpe4sz

View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005508/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900